Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS/GSK's Benlysta Gets Advisory Panel Backing For Lupus Labeling That Reflects Trials' Limitations

This article was originally published in The Pink Sheet Daily

Executive Summary

Arthritis Advisory Committee says belimumab efficacy is not shown for full spectrum of the disease, so the biologic should go to market with appropriate caveats.

You may also be interested in...



GSK Builds Autoimmune R&D With Immutep Deal

Immutep's antibody against recently activated T-lymphocytes could have potential in the treatment of autoimmune diseases.

GSK Builds Autoimmune R&D With Immutep Deal

Immutep's antibody against recently activated T-lymphocytes could have potential in the treatment of autoimmune diseases.

GSK's "Biotech-In-A-Pharma" R&D Model Makes Progress

Since the mid-2000s, GlaxoSmithKline has been working to rejuvenate its R&D organization, which it believed wasn't sufficiently productive. Industry watchers are gauging progress closely, particularly as the cornerstone of its new approach, the division of GSK's drug discovery operations into nearly 40 specialized and idiosyncratic Drug Performance Units, or DPUs, approaches milestone deadlines in 2011, and as the rest of the industry also struggles with R&D productivity.

Topics

UsernamePublicRestriction

Register

PS071451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel